Loading...
Market
Which company will AstraZeneca license its obesity pill to by end of 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Licensing agreements and press releases from AstraZeneca
Story
AstraZeneca's obesity pill shows 5.8% weight loss in early trial, safe and tolerable for type-2 diabetes patients, licensed from Eccogene for $2 billion
Nov 4, 2024, 06:15 PM
AstraZeneca has announced promising results from its experimental obesity pill, which showed a 5.8% reduction in body weight during an early-stage clinical trial. The company reported that the medication was well-tolerated by patients, including those with type-2 diabetes. The trial indicated that side effects were consistent with the GLP-1 drug class, and the pill was deemed safe for use. This medication was licensed from China's Eccogene for up to $2 billion, highlighting AstraZeneca's commitment to expanding its portfolio in weight-loss treatments.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%